Distinct patterns of biomarker expression for atypical intraductal proliferations in prostate cancer

被引：2

作者：

Martini, Carmela ^{[1
]}

Logan, Jessica M. ^{[1
]}

Sorvina, Alexandra ^{[1
]}

Prabhakaran, Sarita ^{[2
]}

Ung, Benjamin S. Y. ^{[1
]}

Johnson, Ian R. D. ^{[1
]}

Hickey, Shane M. ^{[1
]}

Brooks, Robert D. ^{[1
]}

Caruso, Maria C. ^{[1
]}

Klebe, Sonja ^{[2
,3
]}

Karageorgos, Litsa ^{[1
]}

O'Leary, John J. ^{[4
]}

Delahunt, Brett ^{[5
]}

Samaratunga, Hemamali ^{[6
,7
]}

Brooks, Douglas A. ^{[1
,4
]}

机构：

[1] Univ South Australia, Clin & Hlth Sci, Adelaide, SA, Australia

[2] Flinders Univ S Australia, Coll Med & Publ Hlth, Dept Anat Pathol, Adelaide, SA, Australia

[3] Flinders Med Ctr, SA Pathol, Dept Surg Pathol, Adelaide, SA, Australia

[4] Trinity Coll Dublin, Dept Histopathol, Dublin, Ireland

[5] Malaghan Inst Med Res, Wellington, New Zealand

[6] Aquesta Uropathol, Brisbane, Qld, Australia

[7] Univ Queensland, Brisbane, Qld, Australia

来源：

VIRCHOWS ARCHIV | 2024年 / 485卷 / 04期

基金：

澳大利亚国家健康与医学研究理事会;

关键词：

High-grade prostatic intraepithelial neoplasia; Atypical intraductal proliferation; Immunohistochemistry; Biomarkers; Diagnosis; Prostatic adenocarcinoma; NEEDLE-BIOPSY; CARCINOMA;

D O I：

10.1007/s00428-023-03643-1

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

High-grade prostatic intraepithelial neoplasia (HGPIN) is a well-characterised precursor lesion in prostate cancer. The term atypical intraductal proliferations (AIP) describes lesions with features that are far too atypical to be considered HGPIN, yet insufficient to be diagnosed as intraductal carcinoma of the prostate (IDCP). Here, a panel of biomarkers was assessed to provide insights into the biological relationship between IDCP, HGPIN, and AIP and their relevance to current clinicopathological recommendations. Tissue samples from 86 patients with prostate cancer were assessed by routine haematoxylin and eosin staining and immunohistochemistry (IHC) with a biomarker panel (Appl1/Sortilin/Syndecan-1) and a PIN4 cocktail (34 beta E12+P63/ P504S). Appl1 strongly labelled atypical secretory cells, effectively visualising intraductal lesions. Sortilin labelling was moderate-to-strong in > 70% of cases, while Syndecan-1 was moderate-to-strong in micropapillary HGPIN/AIP lesions (83% cases) versus flat/tufting HGPIN (<= 20% cases). Distinct biomarker labelling patterns for atypical intraductal lesions of the prostate were observed, including early atypical changes (flat/tufting HGPIN) and more advanced atypical changes (micropapillary HGPIN/AIP). Furthermore, the biomarker panel may be used as a tool to overcome the diagnostic uncertainty surrounding AIP by supporting a definitive diagnosis of IDCP for such lesions displaying the same biomarker pattern as cribriform IDCP.

引用

页码：723 / 728

页数：6

共 14 条

[1] Bostwick D.G., Liu L., Brawer M.K., Qian J., High-grade prostatic intraepithelial neoplasia, Rev Urol, 6, pp. 171-179, (2004)
[2] Netto G.J., Amin M.B., Berney D.M., Et al., The 2022 World Health Organization classification of tumors of the urinary system and male genital organs-part B: prostate and urinary tract tumors, Eur Urol, 82, pp. 469-482, (2022)
[3] Hickman R.A., Yu H., Li J., Et al., Atypical intraductal cribriform proliferations of the prostate exhibit similar molecular and clinicopathologic characteristics as intraductal carcinoma of the prostate, Am J Surg Pathol, 41, pp. 550-556, (2017)
[4] Morote J., Schwartzmann I., Celma A., Et al., The current recommendation for the management of isolated high-grade prostatic intraepithelial neoplasia, BJU Int, 129, pp. 627-633, (2022)
[5] Shah R.B., Nguyen J.K., Przybycin C.G., Et al., Atypical intraductal proliferation detected in prostate needle biopsy is a marker of unsampled intraductal carcinoma and other adverse pathological features: a prospective clinicopathological study of 62 cases with emphasis on pathological outcomes, Histopathology, 75, pp. 346-353, (2019)
[6] Johnson I.R., Parkinson-Lawrence E.J., Shandala T., Et al., Altered endosome biogenesis in prostate cancer has biomarker potential, Mol Cancer Res, 12, pp. 1851-1862, (2014)
[7] Johnson I.R., Parkinson-Lawrence E.J., Butler L.M., Brooks D.A., Prostate cell lines as models for biomarker discovery: performance of current markers and the search for new biomarkers, Prostate, 74, pp. 547-560, (2014)
[8] Johnson I.R., Parkinson-Lawrence E.J., Keegan H., Et al., Endosomal gene expression: a new indicator for prostate cancer patient prognosis?, Oncotarget, 6, pp. 37919-37929, (2015)
[9] Martini C., Logan J.M., Sorvina A., Et al., Aberrant protein expression of Appl1, Sortilin and Syndecan-1 during the biological progression of prostate cancer, Pathology, 55, pp. 40-51, (2023)
[10] Sorvina A., Martini C., Prabhakaran S., Et al., Appl1, Sortilin and Syndecan-1 immunohistochemistry on intraductal carcinoma of the prostate provides evidence of retrograde spread, Pathology, (2023)

← 1 2 →